Biotech: Page
-
PharmaVoice Team/PharmaVoice
The Next BIG Thing in EDC
The Next BIG Thing in EDC The most compelling evidence for the argument that electronic data capture (EDC) is entering the mass adoption phase of its technology life cycle is the rate at which sponsors and CROs are internalizing the development processes. Technology transfer or in-licensing o...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Table of Contents
Table of contents Letter from the Editor The Forum Biotech: The Perfect Storm — A relatively more favorable funding environment, cutting-edge technologies, and a strong position at the partnership table have many of today’s biotechnology companies in a position for success. Company Listing by Top...
By PharmaVoice Team • Jan. 2, 2008 -
Explore the Trendline➔
Getty Images
TrendlineEmerging biotech
After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
A Robust Future for Phase IV Trials
A Robust Future for Phase IV Trials May 2005 VIEW on Biotechnology Clinical Trials Dimensional HealthCare Inc., Cedar Knolls, N.J., designs, implements, and provides community-based research to the pharmaceutical and medical-device industries, focusing on the design and implementation of la...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Branding Your Company -- Right from the Start
Branding Your Company — Right from the Start Executives of emerging biotech companies face myriad challenges. While they may certainly understand the value of branding and marketing, those functions may command less of their attention during the early stages of company development than the challe...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Marketing Strategies for Emerging Companies: Lessons from the Maine Wilderness
Marketing Strategies for Emerging Companies: Lessons from the Maine Wilderness for Biotech and Biopharma I do not consider a sale complete until the goods are worn out and the customer (sic) is still satisfied.” When Leon Leonwood Bean posted those words in his humble Maine store in 1916 he wa...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Strategic Phase II Planning -- More Important Than Ever for the Biotech Industry
Strategic Phase II Planning — More Important Than Ever for the Biotech Industry Lukas Makris, Ph.D. CEO Phase II programs should not only be judged on how well the objectives were met, but on how well they might predict the Phase III outcome. The biotechnology industr...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Personalized Medicine: Our Industry's Next Great Leap Forward
Personalized Medicine: Our Industry’s Next Great Leap Forward Marketing Personalized medicine will drive medicine to become much more of a science than an art. And with that change, there will be many necessary fundamental changes to how our industry markets these innovations. Ri...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Cover
PharmaVOICE The Forum for the Industry Executive Year In Preview: 2005 More than 100 experts talk about the industry’s future www.pharmavoice.com December 2004 Special Issue Volume 4 Number 12 Download PDF
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
February 15-17 WCBF Six Sigma in Chemicals & Pharmaceuticals Hyatt Regency Dallas, Dallas For more information, contact Louise Gosling, WCBF Six Sigma Solutions, at 44-14-83 76-0883, e-mail [email protected], or visit wcbf.com. February 15-18 18th Annual DIA Electronic Document Manageme...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
What's on Your Mind -- Opinions
Opinions More on Leadership Development PharmaVOICE received such an overwhelming response to our leadership development opinion question — how executives throughout the industry develop leaders — for the April issue, we are pleased to publish additional insights on this hot topic. Entrepreneuria...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
The Art of the Deal
The biotech industry is in a much stronger position now than it was in its early days, and today biotech companies enjoy a prominent seat at the negotiation table. Biotech companies, especially those with products, are asking for true collaboration instead of relying on licensing deals. The days ...
By Denise Myshko • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Table of Contents
On the Cover Culture of compliance: Cutting through the confusion To be compliant with the many regulations and guidances that apply to the marketing of prescription products, companies need to create a culture of compliance that fosters and promotes an ethical atmosphere and compliant behavior. ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Matthew E. Czajkowski aaiPharma Appoints Executive VP, Chief Financial Officer Matthew E. Czajkowski has been appointed executive VP and chief financial officer of aaiPharma, Wilmington, N.C., a science-based pharmaceutical company focused on pain management. Mr. Czajkowski, 55, previ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Medical Education
Medical Education Nash-Wong. Last year’s predictions on regulatory changes had us believing medical education was a thing of the past. Not so, if one considers the fact that physicians continue to attend educational meetings, despite limited food budgets and a ban on spouses. So rather than forec...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Multifunctional Teams
Multifunctional Teams Wilson. Historically, the pharmaceutical industry has faced two hurdles: achieving product registration and securing reimbursement. Today, demonstrating product value is becoming a much stronger issue. It’s not just a matter of product price, but the impact on total cost of ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Technology
Technology Cauwenbergh. Ideally, predictive tools, including assays, computer modeling techniques, and biomarkers could shorten development time, reduce the cost of development, and increase the accuracy of diagnosis, making sure that the right patient gets the right drug because of proper diagno...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Risk Management
Risk Management Turett. The term risk management implies a defensive, prepare-for-the-worst strategy. While defensive preparation is certainly important, taking a fresh look at conducting business in a “patient-first” manner will reduce the need to implement a defensive approach. In other words, ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Business Models
Turett. The pharmaceutical industry needs to resolve multiple bipolarities: being a business and being a public utility; being doctor-focused and being consumer-focused; and being about medical innovation and being about marketing. The industry has begun a process of self-reinvention that in 2005...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Introduction
The Pulse of the Industry By Taren Grom This first annual PharmaVOICE Year in PreVIEW is designed to provide an overview of the challenges and trends expected to impact the life-sciences industry in the coming year and beyond. For this special forum, a distinguished list of more than 100 industry...
By Taren Grom • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
2005 Year In Preview Taren Grom In keeping with PharmaVOICE’s mission of providing insightful and provocative commentary on the business practices, strategies, and services that affect the life cycle of products from molecule through market, it is our pleasure to publish the first annual Year in ...
By Taren Grom • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Table of Contents
Contents Kristine Nash-Wong, Marketing Manager at HealthMedia, speaks about reputation enhancement. Dr. Thomas Wicks, VP of Regulatory Affairs at Odyssey Pharmaceuticals, talks about continuing treatment innovation while limiting costs. Scott Szwast, Sector Marketing Manager at UPS Supply Chain S...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Global Perspective
Is Japan on the Verge of a Biotech Boom? A growing number of biopharma start-up companies are looking beyond the United States and Europe for business opportunities. And one market that is generating a lot of buzz in biotech today is Japan. One of the more under-reported business stories of the p...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Chief Risk Officers: Time for a Seat at The Table
VIEW on risk management Chief Risk Officers Time for a Seat at the Table In the wake of year one Sarbanes-Oxley compliance for U.S. public companies, there are greater challenges and increased expectations in addressing enterprise risk. Yet, compliance is not a matter of completing a one-year pro...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Drug Importation Poses Risks A federal HHS Task Force has warned in its Report on Prescription Drug Importation against the public health risks and economic effects of legalizing the importation of drugs from Canada and other countries with price controls. “This study confirms the deep flaws inhe...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
Pharma’s Clouds Aren’t Darkening the Employee Recruitment Outlook Contributed by Julie B. Kampf Massive product safety recalls; costly accounting and pricing violations; embarrassing marketing and sales transgressions — is the beleaguered pharmaceutical sector an executive recruiter’s nightmare? ...
By Julie B. Kampf • Jan. 2, 2008
Previous
